For how we live.
In the GSK-funded phase 3 MATINEE trial, the anti-IL-5 antibody lowered moderate or severe exacerbations from 1.01 to 0.80 a year — but symptom and quality-of-life endpoints showed no significant benefit.
The PURE study measured airflow obstruction in adults across 25 countries and found most cases had never been labelled, with the largest undiagnosed share in lower-income settings.
Two large trials, ETHOS and IMPACT, found adding an inhaled steroid to a two-bronchodilator inhaler lowered exacerbation rates in COPD — at the cost of more pneumonia.
A 1,695-patient trial tested whether metoprolol helps people with COPD and no cardiovascular indication. It missed its primary endpoint — but, unlike an earlier trial, showed no signal of harm.
The federal program enrols nearly 140,000 responders and survivors, most certified for a 9/11-related illness. Cohort data show a heavy, still-growing burden — and hint the program itself lowers mortality.
Sensors and reminder inhalers get patients to take more doses — one trial lifted adherence from 30% to 84%. That this translates into meaningfully better control is real but a smaller effect.
Tozorakimab, which blocks interleukin-33, lowered the rate of moderate or severe COPD exacerbations by about a third against placebo, without an eosinophil requirement to qualify.
A WHO data-set analysis shows how mobile and hospital teams split the load of hypertension, diabetes and epilepsy care during the war, while a separate study tracked dialysis capacity falling.
Fine particulate exposure in seven Amazonian capitals was tied to about 5,472 circulatory and 2,621 respiratory deaths over six years. A separate analysis finds cardiac mortality rising with forest loss.
Two large trials of the anti-ST2 antibody gave discordant results: a modest signal in the phase 2b study, and a missed primary endpoint for the same dose in the confirmatory phase 3.
Two February papers put respiratory virus activity into the models. One finds pollution effects amplified at peak influenza; the other finds them attenuated when rhinovirus is high.
Cedars-Sinai counted a 118% rise in general-illness visits and a 46% rise in heart attack visits over the 90 days after the fires started. Abnormal blood results more than doubled.